How much will Iridium shareholders receive, and does the value change with Rocket Lab's share price?

Each Iridium share receives $27.00 in cash plus RKLB stock. Within the $67.50 to $112.50 collar, the stock is valued at a fixed $27.00, so total value stays at about $54.00 per share regardless of RKLB's price. Below $67.50 the exchange ratio is fixed at 0.4000, so the stock component is worth less than $27.00 and total value falls with RKLB's price. Above $112.50 the ratio is fixed at 0.2400, so the stock component is worth more than $27.00 and total value rises.

How will Rocket Lab pay for the cash portion and what does it mean for its balance sheet?

Rocket Lab has committed a $3.6 billion 364-day senior secured bridge loan and intends to fund the cash component from existing cash plus other debt and equity financing. The filing does not disclose the total cash requirement, the mix of financing, or pro forma leverage. A bridge loan of this size would typically be refinanced with longer-term debt or equity, which could affect dilution and interest costs.

What are the main risks that could prevent the deal from closing?

Key risks include failure to obtain Iridium stockholder approval, HSR and FCC clearances, and foreign investment and satellite approvals. Other risks are the emergence of a superior proposal, a change in Iridium's board recommendation, litigation, an ineffective S-4, and the tax-free reorganization condition, which depends on the cash-to-stock value balance at closing. If the deal fails, Iridium may owe a $223.62 million termination fee in certain cases.

What does Iridium contribute financially, and what does Rocket Lab claim about accretion?

Per the companies' disclosure, Iridium generated $871.7 million of 2025 revenue and $495 million of OEBITDA, a 57% margin. Rocket Lab describes the deal as significantly accretive to cash flow generation and profitability. The filing does not provide pro forma EPS, synergy estimates, or detailed purchase accounting, so accretion claims cannot be independently verified from this document.

How much support does the deal have, and what protects it from competing bids?

The boards of both companies unanimously approved the transaction. Iridium directors holding about 1.6% of outstanding shares signed support agreements to vote in favor. Iridium is subject to a no-shop restriction, but may consider an unsolicited superior proposal and terminate for one, subject to the fee. The support agreements terminate if the board withdraws its recommendation or if the merger agreement is amended in a way that reduces consideration.

RKLB 8-K: Material Agreements & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed June 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Rocket Lab (RKLB) has agreed to acquire Iridium Communications (IRDM) in a cash-and-stock merger valued at a notional $54.00^a per Iridium share, or an enterprise value of about $8.0 billion.

Each Iridium share will receive $27.00^b in cash plus Rocket Lab stock under a collared exchange ratio: 0.4000 shares if RKLB's 10-day VWAP is at or below $67.50, a fixed-value ratio of $27.00 divided by the VWAP between $67.50 and $112.50, and 0.2400 shares at or above $112.50. Within the collar, the stock component is worth a fixed $27.00, so Iridium holders are protected from RKLB price moves in that band. Outside it, the value floats: below $67.50 the stock component is worth less than $27.00, and above $112.50 it is worth more.

The transaction is structured as a two-step merger intended to qualify as a tax-free reorganization, though that treatment depends on the cash-to-stock value mix at closing. The deal is financed in part by a $3.6 billion^c 364-day senior secured bridge loan from Deutsche Bank and Wells Fargo, with the balance of the cash component to come from Rocket Lab's balance sheet and other debt or equity sources. Rocket Lab's cash position and leverage will therefore change materially if the deal closes, and the filing does not quantify the total cash requirement or post-closing leverage.

Completion requires Iridium stockholder approval, HSR clearance, FCC consent for the transfer of control of Iridium's telecom authorizations, several foreign investment and satellite approvals, and an effective Form S-4 registration covering the RKLB shares to be issued. The outside date is June 28, 2027, extendable to September and December 2027. Iridium owes Rocket Lab a $223.62 million^d termination fee in specified circumstances, including a superior proposal or an adverse board recommendation change.

Iridium's 2025 revenue was $871.7 million with OEBITDA of $495 million (57% margin), per the companies, which Rocket Lab frames as a source of recurring cash flow and accretion. Directors holding about 1.6% of Iridium shares have signed support agreements. Management expects closing in mid-2027.

02—Key points

Key Highlights

Headline value: $54.00 per Iridium share (notional), consisting of $27.00 cash plus a variable number of RKLB shares, implying an enterprise value of about $8.0 billion.
Exchange ratio collar: 0.4000 RKLB shares at or below $67.50; $27.00 divided by the 10-day VWAP between $67.50 and $112.50; 0.2400 shares at or above $112.50. The stock component is fixed at $27.00 within the collar.
Financing: $3.6 billion 364-day senior secured bridge term loan committed by Deutsche Bank AG and Wells Fargo Bank, with the cash balance to be funded from Rocket Lab's balance sheet and other debt or equity sources.
Termination fee of $223.62 million payable by Iridium to Rocket Lab in specified circumstances, including a superior proposal or adverse recommendation change; a tail provision applies for deals struck within one year.
Key closing conditions: Iridium stockholder majority vote, HSR waiting period expiration, FCC consent for transfer of control of Iridium's telecom authorizations, foreign approvals, an effective Form S-4, and Nasdaq listing approval for new RKLB shares.
Strategic rationale per management: vertical integration from launch through spectrum and LEO network operations, entry into recurring satellite-services revenue, and access to Iridium's L-band spectrum and roughly 2.55 million subscribers.
Outside date of June 28, 2027, extendable to September 28, 2027 and December 28, 2027; expected closing timing is mid-2027, leaving limited cushion if regulatory reviews run long.

03—Questions

Frequently Asked Questions

How much will Iridium shareholders receive, and does the value change with Rocket Lab's share price?
Each Iridium share receives $27.00 in cash plus RKLB stock. Within the $67.50 to $112.50 collar, the stock is valued at a fixed $27.00, so total value stays at about $54.00 per share regardless of RKLB's price. Below $67.50 the exchange ratio is fixed at 0.4000, so the stock component is worth less than $27.00 and total value falls with RKLB's price. Above $112.50 the ratio is fixed at 0.2400, so the stock component is worth more than $27.00 and total value rises.
How will Rocket Lab pay for the cash portion and what does it mean for its balance sheet?
Rocket Lab has committed a $3.6 billion 364-day senior secured bridge loan and intends to fund the cash component from existing cash plus other debt and equity financing. The filing does not disclose the total cash requirement, the mix of financing, or pro forma leverage. A bridge loan of this size would typically be refinanced with longer-term debt or equity, which could affect dilution and interest costs.
What are the main risks that could prevent the deal from closing?
Key risks include failure to obtain Iridium stockholder approval, HSR and FCC clearances, and foreign investment and satellite approvals. Other risks are the emergence of a superior proposal, a change in Iridium's board recommendation, litigation, an ineffective S-4, and the tax-free reorganization condition, which depends on the cash-to-stock value balance at closing. If the deal fails, Iridium may owe a $223.62 million termination fee in certain cases.
What does Iridium contribute financially, and what does Rocket Lab claim about accretion?
Per the companies' disclosure, Iridium generated $871.7 million of 2025 revenue and $495 million of OEBITDA, a 57% margin. Rocket Lab describes the deal as significantly accretive to cash flow generation and profitability. The filing does not provide pro forma EPS, synergy estimates, or detailed purchase accounting, so accretion claims cannot be independently verified from this document.
How much support does the deal have, and what protects it from competing bids?
The boards of both companies unanimously approved the transaction. Iridium directors holding about 1.6% of outstanding shares signed support agreements to vote in favor. Iridium is subject to a no-shop restriction, but may consider an unsolicited superior proposal and terminate for one, subject to the fee. The support agreements terminate if the board withdraws its recommendation or if the merger agreement is amended in a way that reduces consideration.

04—Continue

← View all 8-K filings